JAGX
(NASDAQ)
0.4524
+0.0102  (+2.26%)
Volume (24h): 3.49M Day Range: 0.4430 - 0.4700
Market Cap: 9.59M 52W Range: 0.1223 - 17.00
May-28-20 12:30PM Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in DogsACCESSWIRE
May-26-20 12:30PM Jaguar Health Sustainability Leader Interviewed on Foodie Pharmacology PodcastACCESSWIRE
May-22-20 01:00PM Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross ProceedsACCESSWIRE
May-20-20 12:30PM Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug ProductACCESSWIRE
May-15-20 08:15PM Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of StockholdersACCESSWIRE
12:00PM Jaguar Health, Inc. Reports 2020 First Quarter Financial ResultsACCESSWIRE
May-13-20 12:30PM Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLCACCESSWIRE
May-12-20 03:45PM Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business UpdatesACCESSWIRE
12:30PM Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in DogsACCESSWIRE
May-03-20 08:11PM Pricing of Covid-19 Products Will Face Public ScrutinyGuruFocus.com
Apr-29-20 03:58AM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
Apr-28-20 11:48PM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
Apr-16-20 12:30PM Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug CandidateACCESSWIRE
Apr-13-20 11:31PM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
07:12PM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
Apr-07-20 09:10PM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
03:00PM Edited Transcript of JAGX earnings conference call or presentation 6-Apr-20 12:30pm GMTThomson Reuters StreetEvents
Apr-06-20 12:00PM Jaguar Health Reports 2019 Financial Results and Business UpdatesACCESSWIRE
Apr-03-20 12:30PM Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business UpdatesACCESSWIRE
Apr-02-20 12:30PM Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support ProgramACCESSWIRE
Apr-01-20 12:30PM Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in DogsACCESSWIRE
Mar-12-20 12:30PM Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. EasternACCESSWIRE
Mar-09-20 05:46PM The Jaguar Health (NASDAQ:JAGX) Share Price Is Down 95% So Some Shareholders Are Very SaltySimply Wall St.
Mar-05-20 01:30PM Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue StreamACCESSWIRE
Feb-20-20 01:45PM Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research AwardACCESSWIRE
Feb-06-20 01:30PM Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. EasternACCESSWIRE
Jan-08-20 01:30PM Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel SyndromeACCESSWIRE
Jan-07-20 01:50PM One Thing To Remember About The Jaguar Health, Inc. (NASDAQ:JAGX) Share PriceSimply Wall St.
Dec-16-19 01:30PM Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV PatientsACCESSWIRE
Dec-10-19 01:30PM Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. EasternACCESSWIRE
Nov-21-19 01:30PM Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. EasternACCESSWIRE
Nov-20-19 02:15PM Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review MagazineACCESSWIRE
02:00PM MicroCap Review Magazine Fall 2019 Issue Now AvailableACCESSWIRE
Nov-14-19 01:30PM Jaguar Health, Inc. Reports 2019 Third Quarter Financial ResultsACCESSWIRE
01:00PM Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer PatientsACCESSWIRE
Nov-13-19 01:30PM Jaguar Health Appoints Ian Wendt Vice President, Commercial StrategyACCESSWIRE
Nov-12-19 01:30PM Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business UpdatesACCESSWIRE
Nov-05-19 12:30PM 14 Low Float Stocks With High Short InterestBenzinga
Oct-30-19 12:30PM Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.ACCESSWIRE
Oct-23-19 12:30PM Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious DiarrheaACCESSWIRE
Oct-22-19 12:43PM Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKIACCESSWIRE
Oct-18-19 02:23PM These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this yearAmerican City Business Journals
Oct-15-19 12:00PM MicroCap Rodeo Investor Conference - Lineup for October 15 and 16, 2019ACCESSWIRE
Oct-11-19 12:14PM The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug ReadoutBenzinga
Oct-10-19 12:30PM Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in ChinaACCESSWIRE
Oct-04-19 12:30PM Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and CrofelemerACCESSWIRE
Oct-03-19 11:34AM The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For OrganovoBenzinga
Oct-01-19 12:30PM Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in DogsACCESSWIRE
Sep-30-19 02:16PM The Jaguar Health (NASDAQ:JAGX) Share Price Is Down 98% So Some Shareholders Are Very SaltySimply Wall St.
12:30PM Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent ApplicationACCESSWIRE
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)